In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Crispr Therapeutics AG, with a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Hold rating due to a combination of factors including the current momentum in Casgevy’s sales and patient metrics, which are showing signs of growth but still require significant ramp-up to justify the valuation. The company has reported $30 million in sales from 16 patients, with 35 additional patients beginning treatment in the second quarter, indicating a need for continued expansion to meet expectations.
Moreover, Crispr Therapeutics AG is expected to release data on CTX112 in NHL and AID in the second half of the year, alongside updates on other programs like CTX131 and CTX211. The inclusion of CTX310 in the model and the increase in price target to $40 reflect these developments, yet the overall outlook suggests a cautious approach, hence the Hold rating.
According to TipRanks, Van Buren is an analyst with an average return of -2.1% and a 42.53% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Regeneron.
In another report released on July 31, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $60.00 price target.